Trials / Completed
CompletedNCT02231918
Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)
An Open-label Clinical Study to Investigate Pharmacokinetics (PK) of Different Doses (0.125 mg, 0.25 mg, 0.5 mg) of Pramipexole Administered Once Daily Orally in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 6 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
Study to determine the pharmacokinetics (PK) of pramipexole (PPX) after administration of a single dose orally (p.o.) in pediatric patients with the diagnosis of RLS
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MIRAPEX® - low | |
| DRUG | MIRAPEX® - medium | |
| DRUG | MIRAPEX® - high |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-07-01
- First posted
- 2014-09-04
- Last updated
- 2015-10-06
- Results posted
- 2015-10-06
Source: ClinicalTrials.gov record NCT02231918. Inclusion in this directory is not an endorsement.